S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Baxter International Third Quarter 2014 Financial Results Conference Call|
|Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A|
|Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398|
|Baxter to Form New Global Innovation and R&D Center near Boston for Its Biopharmaceuticals Business|
|Baxter Recognized for Commitment to Women's Healthcare Careers|
|Baxter Announces Filing of Form 10 Registration Statement in Connection with Planned Spin off of Biopharmaceuticals Business|
|Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency|
|FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A|
|Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability Endpoints in Phase 2/3 Study|
|Baxter to Present at the 2014 Credit Suisse Healthcare Conference|
Click above to view more mutual fund data and stats for bax - Baxter International Inc.